Last reviewed · How we verify
Azixa
Azixa is a Small molecule drug developed by Myrexis Inc.. It is currently in Phase 2 development. Also known as: MPC-6827.
Azixa, also known as Verubulin, is a small molecule used in clinical trials for the treatment of various conditions, including Glioblastoma Multiforme, Metastatic Melanoma, Refractory Solid Tumors, and Brain Neoplasms. It has been studied in combination with other treatments such as Temozolomide and Radiation Therapy in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Azixa |
|---|---|
| Also known as | MPC-6827 |
| Sponsor | Myrexis Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Exploratory Evaluation of [11C]MPC6827 (EARLY_PHASE1)
- Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2)
- Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme (PHASE2)
- Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme (PHASE1, PHASE2)
- Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma (PHASE1, PHASE2)
- Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors (PHASE1)
- Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Azixa CI brief — competitive landscape report
- Azixa updates RSS · CI watch RSS
- Myrexis Inc. portfolio CI
Frequently asked questions about Azixa
What is Azixa?
Who makes Azixa?
Is Azixa also known as anything else?
What development phase is Azixa in?
Related
- Manufacturer: Myrexis Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: MPC-6827
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing